Skip to content
Home
About Us
Contributors
Publications
Aron 1 – Renal Cell Carcinoma
Aron 2 – Urothelial carcinoma
Aron 3 – Prostate Cancer
Aron – supplementaries
Contact Us
Menu
Home
About Us
Contributors
Publications
Aron 1 – Renal Cell Carcinoma
Aron 2 – Urothelial carcinoma
Aron 3 – Prostate Cancer
Aron – supplementaries
Contact Us
Publications
All our publications
Infusion-Related Reactions Among Cancer Patients Receiving Immune Checkpoint Inhibitors: The ARON-MOUSEION-013 Systematic Review and Meta-Analysis
Vitale E, et al.
Drug Des Devel Ther
2025
Decreased Appetite in Cancer Patients Treated with immune checkpoint inhibitors (ICIs): The MOUSEION-012 Systematic Review and Meta-Analysis
Vitale E, et al.
Clin Nutr ESPEN
2025
Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study
Buttner T, et al.
Prostate Cancer Prostatic Dis.
2026
Lu-PSMA vs. cabazitaxel in patients with castration-resistant prostate cancer: Real-world efficacy and safety data from the ARON-3 study
Mandel P, et al.
Eur J Cancer.
2025
Bone metastases in advanced urothelial carcinoma patients receiving enfortumab vedotin: A Real-World study from the ARON-2EV project
Rizzo A, et al
Clin Exp Med
2025
Time to metastasis as a prognostic factor in metastatic urothelial carcinoma: results from the ARON-2 study
Pichler R, et al
Clin Exp Metastasis
2025
Previous
Page
1
Page
2
Page
3
Page
4
Page
5
Next
